FTO genotype was associated with breast cancer in HER2 negative patients

被引:3
|
作者
Montazeri, Fateme [1 ]
Hatami, Hossein [7 ,8 ]
Fathi, Soroor [9 ]
Ardekanizadeh, Naeemeh Hasanpour [3 ]
Bourbour, Fatemeh [2 ,4 ]
Rastgoo, Samira [2 ,4 ]
Shafiee, Fatemeh [5 ]
Akbari, Mohammad Esmail [6 ]
Gholamalizadeh, Maryam [6 ]
Jarrahi, Seyed Alireza Mosavi [6 ]
Doaei, Saeid [6 ,10 ]
机构
[1] Shahid Beheshti Univ Med Sci, Sch Med, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Fac Nutr & Food Technol, Natl Nutr & Food Technol Res Inst, Dept Clin Nutr & Dietet, Tehran, Iran
[3] Shiraz Univ Med Sci, Sch Nutr & Food Sci, Dept Clin Nutr, Shiraz, Iran
[4] Shahid Beheshti Univ Med Sci, Dept Clin Nutr & Dietet, Res Inst, Tehran, Iran
[5] Shiraz Univ Med Sci, Nutr Res Ctr, Sch Nutr & Food Sci, Shiraz, Iran
[6] Shahid Beheshti Univ Med Sci, Canc Res Ctr, Tehran, Iran
[7] Shahid Beheshti Univ Med Sci, Sch Publ Hlth & Safety, Dept Publ Hlth, Tehran, Iran
[8] Shahid Beheshti Univ Med Sci, Environm & Occupat Hazards Control Res Ctr, Tehran, Iran
[9] Isfahan Univ Med Sci, Sch Nutr & Food Sci, Dept Community Nutr, Esfahan, Iran
[10] Guilan Univ Med Sci, Al Zahra Hosp, Reprod Hlth Res Ctr, Sch Med,Dept Obstet & Gynecol, Rasht, Iran
关键词
FTO; rs9939609; Breast cancer; HER2; GENETIC SUSCEPTIBILITY; OBESITY;
D O I
10.1016/j.clnesp.2022.02.122
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: The fat mass and obesity-associated (FTO) gene may influence the risk of breast cancer (BC). The single nucleotide polymorphisms (SNPs) of FTO gene may exert different impacts on different types of BC. In this study, we investigated the association between FTO SNP rs9939609 and the status of estrogen receptor (ER), progesterone receptor (PR), P53, and human epidermal growth factor receptor-2 (HER-2) in BC patients. Methods: Our case-control study was included 540 Iranian participants aged 35 to 70 (180 women with BC as the case group and 360 healthy controls). After genotyping for risk allele rs9939609 of the FTO gene, a logistic regression was applied to elucidate the association between FTO SNP rs9939609 and BC risk based on the receptor status. Results: The number of HER-2 negative patients was significantly higher in FTO rs9939609 risk allele carrier group (61.5% vs. 41.4%, P < 0.05). A significant association was found between BC and rs9939609 FTO gene polymorphism only in HER2 negative BC patients (OR = 1.79, CI95%: 1.2-3.56, P = 0.03). No association was identified between FTO rs9939609 polymorphism and the status of ER, PR, and P53. Conclusion: We indicated that FTO SNP rs9939609 can be a potential therapeutic target particularly in HER-2 negative BC cases. The importance of this risk allele in BC pathogenesis needs to be further highlighted. (c) 2022 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:495 / 498
页数:4
相关论文
共 50 条
  • [1] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [2] HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients
    Endo, Yumi
    Dong, Yu
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Yamashita, Hiroko
    Sato, Shinya
    Takahashi, Satoru
    Fujii, Yoshitaka
    Toyama, Tatsuya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (07) : 619 - 623
  • [3] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Sasagu Kurozumi
    Mary Padilla
    Masafumi Kurosumi
    Hiroshi Matsumoto
    Kenichi Inoue
    Jun Horiguchi
    Izumi Takeyoshi
    Tetsunari Oyama
    Jim Ranger-Moore
    D. Craig Allred
    Eslie Dennis
    Hiroaki Nitta
    Breast Cancer Research and Treatment, 2016, 158 : 99 - 111
  • [4] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Kurozumi, Sasagu
    Padilla, Mary
    Kurosumi, Masafumi
    Matsumoto, Hiroshi
    Inoue, Kenichi
    Horiguchi, Jun
    Takeyoshi, Izumi
    Oyama, Tetsunari
    Ranger-Moore, Jim
    Allred, D. Craig
    Dennis, Eslie
    Nitta, Hiroaki
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 99 - 111
  • [5] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Cicin, Irfan
    Karagol, Hakan
    Usta, Ufuk
    Sezer, Atakan
    Uzunoglu, Sernaz
    Alas-Cosar, Rusen
    Yetisyigit, Tarkan
    Uygun, Kazim
    MEDICAL ONCOLOGY, 2009, 26 (03) : 335 - 343
  • [6] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Irfan Cicin
    Hakan Karagol
    Ufuk Usta
    Atakan Sezer
    Sernaz Uzunoglu
    Rusen Alas-Cosar
    Tarkan Yetisyigit
    Kazim Uygun
    Medical Oncology, 2009, 26 : 335 - 343
  • [7] Analysis of 47 Patients with Triple Negative (ER, PGR, HER2) Breast Cancer
    Gunes, Mehmet Emin
    Celik, Gurhan
    Trabulus, Fadime Didem
    Aksoy, Sefika
    Ozoran, Emre
    Aren, Acar
    Gucin, Zuhal
    Bahadir, Fadime
    ISTANBUL MEDICAL JOURNAL, 2012, 13 (04): : 166 - 168
  • [8] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
  • [9] Treatment of HER2 positive breast cancer patients
    Matos, Erika
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2012, 81 (03): : 236 - 245
  • [10] HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer
    Mazumder, Aloran
    Shiao, Stephen
    Haricharan, Svasti
    ENDOCRINOLOGY, 2021, 162 (10)